Michael Pishvaian

21PUBLICATIONS
190CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jun 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

|Mar 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

|Mar 19, 2026
The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.

Valerie Lee, Apoorvaa S Sachidanand, Christina Rodriguez

|Sep 10, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Jennifer J Knox, Grainne O'Kane, Daniel King

|Aug 20, 2025
Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer.

Matthew I Ebia, Edik M Blais, Yujie Cui

|Jun 16, 2025
Tumor-Treating Fields Open the Door to Progress for Patients With Locally Advanced Pancreatic Cancer.

Michael J Pishvaian

Pageof 4

Frequent Collaborators

6 joint publications

Daniel Laheru

4 joint publications

Dung T Le

3 joint publications

Andrew J Aguirre

3 joint publications

Harshabad Singh